A Phase 4 interventional study of travoprost ophthalmic solution 0.004% and travoprost 0.004% / timolol 0.5% combination ophthalmic solution in Glaucoma, Open-Angle and Ocular Hypertension, sponsored by Allergan. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-08-15.
Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing travoprost in Glaucoma, Open-Angle — 2 open to participants now, 3 under way, 1 of them phase 3. Travoprost · Glaucoma, Open-Angle.
Among the 46 studies testing travoprost in Glaucoma, Open-Angle, this one is the 23rd largest by enrollment of the 45 interventional ones that give a count, is one of 9 that started in 2011, is one of 22 in phase 4, and was the 35th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →2 of the 46 studies testing travoprost in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:
Jonathon Myers · Sites in United States
Ages 18+
Glaukos Corporation · Sites in United States
Ages 45+
By country, each count listing its studies:
Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 9 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 135 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 135 across the 45 interventional studies. Of the 43 that completed or were terminated, 23 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 46 have an industry lead sponsor. The 10 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
58 studies in Glaucoma, Open-Angle by AbbVie: 1 open now, 3 under way, 1 of them phase 3. Of 54 finished, 42 (78%) have results posted.
Among the 58 studies in Glaucoma, Open-Angle by AbbVie, this one is the 20th largest by enrollment of the 34 interventional ones that give a count, is one of 8 that started in 2011, is one of 14 in phase 4, and was the 20th registered.
AbbVie’s Glaucoma, Open-Angle studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 46 studies testing travoprost in Glaucoma, Open-Angle, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 58 in Glaucoma, Open-Angle:
This tab as a report to print or save as PDF → With an account.
This non-inferiority study will assess safety and efficacy of LUMIGAN® RC (bimatoprost ophthalmic solution 0.01%) versus DuoTrav® (travoprost 0.004%/timolol 0.5% combination ophthalmic solution) in patients previously on Travatan® Z (travoprost ophthalmic solution 0.004%) monotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Travatan® Z (travoprost ophthalmic solution 0.004%) administered as 1 drop in the affected eye(s) once a day for 4 weeks. Then, LUMIGAN® RC (bimatoprost ophthalmic solution 0.01%) administered as 1 drop in the affected eye(s) once daily in the evening for 12 weeks.
Drug: travoprost ophthalmic solution 0.004% · Drug: Bimatoprost ophthalmic solution 0.01%
Travatan® Z (travoprost ophthalmic solution 0.004%) administered as 1 drop in the affected eye(s) once a day for 4 weeks. Then, DuoTrav® (travoprost 0.004% / timolol 0.5% combination ophthalmic solution) administered as 1 drop in the affected eye(s) once daily in the morning for 12 weeks.
Drug: travoprost ophthalmic solution 0.004% · Drug: travoprost 0.004% / timolol 0.5% combination ophthalmic solution
Travatan® Z (travoprost ophthalmic solution 0.004%) administered as 1 drop in the affected eye(s) once a day for 4 weeks.
Also known as: Travatan® Z
Drug page: Travoprost
DuoTrav® (travoprost 0.004% / timolol 0.5% combination ophthalmic solution) administered as 1 drop in the affected eye(s) once daily in the morning for 12 weeks.
Also known as: DuoTrav®
LUMIGAN® RC (bimatoprost ophthalmic solution 0.01%) administered as 1 drop in the affected eye(s) once daily in the evening for 12 weeks.
Also known as: LUMIGAN® RC
Mean Diurnal Intraocular Pressure (IOP)
IOP is a measurement of the fluid pressure inside the eye. The mean diurnal IOP was the average of the IOP values of the study eye (worse eye) at Week 12 measured at 8 AM, 12 Noon and 4 PM. For each study eye, IOP was either the average of 2 measurements, or, if a third measurement was required, the average of 3 measurements.
Time frame: Week 12
Change From Baseline in Mean IOP at Week 12
IOP is a measurement of the fluid pressure inside the eye. IOP of the study eye (worse eye) was measured at 8 AM, 12 Noon and 4 PM at Week 12. For each eye, IOP was either the average of 2 measurements, or, if a third measurement was required, the average of 3 measurements. A negative change from Baseline indicated improvement.
Time frame: Baseline, Week 12
Percentage of Participants With ≥15% Reduction in Mean Diurnal IOP From Baseline
IOP is a measurement of the fluid pressure in the eye. The mean diurnal IOP was the average of the IOP values of the study eye (worse eye) measured at 8 AM, 12 Noon and 4 PM. For each eye, IOP was either the average of 2 measurements, or, if a third measurement was required, the average of 3 measurements.
Time frame: Baseline, Week 12
Percentage of Participants With Mean Diurnal IOP Less Than 18 mmHg
IOP is a measure of the fluid pressure in the eye. The mean diurnal IOP was the average of the IOP values of the study eye (worse eye) at Week 12 measured at 8 AM, 12 Noon and 4 PM. For each eye, IOP was either the average of 2 measurements, or, if a third measurement was required, the average of 3 measurements.
Time frame: Week 12
Change From Baseline in Mean IOP at Week 6
IOP is a measurement of the fluid pressure inside the eye. IOP of the study eye (worse eye) was measured at 8 AM, 12 Noon and 4 PM at Week 6. For each eye, IOP was either the average of 2 measurements, or, if a third measurement was required, the average of 3 measurements. A negative change from Baseline indicated improvement.
Time frame: Baseline, Week 6
| Milestone | LUMIGAN® RC | DuoTrav® |
|---|---|---|
| Started | 67 | 68 |
| Completed | 61 | 63 |
| Not completed | 6 | 5 |
| Withdrew: Withdrew consent | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Other miscellaneous reasons | 2 | 1 |
IOP is a measurement of the fluid pressure inside the eye. The mean diurnal IOP was the average of the IOP values of the study eye (worse eye) at Week 12 measured at 8 AM, 12 Noon and 4 PM. For each study eye, IOP was either the average of 2 measurements, or, if a third measurement was required, the average of 3 measurements.
| mmHg | LUMIGAN® RC | DuoTrav® |
|---|---|---|
| Mean Diurnal Intraocular Pressure (IOP) | 18.6 ± 3.5 | 17.4 ± 2.7 |
IOP is a measurement of the fluid pressure inside the eye. IOP of the study eye (worse eye) was measured at 8 AM, 12 Noon and 4 PM at Week 12. For each eye, IOP was either the average of 2 measurements, or, if a third measurement was required, the average of 3 measurements. A negative change from Baseline indicated improvement.
| mmHg | LUMIGAN® RC | DuoTrav® |
|---|---|---|
| Baseline_8 AM | 22.0 ± 2.9 | 22.0 ± 4.1 |
| Change from Baseline at Week 12 _8 AM (n=61,63) | -2.7 ± 3.4 | -4.5 ± 3.1 |
| Baseline_12 Noon | 20.6 ± 3.2 | 20.3 ± 3.8 |
| Change from Baseline at Week 12_12 Noon (n=61,63) | -1.9 ± 3.1 | -2.3 ± 3.2 |
| Baseline_4 PM | 19.8 ± 3.1 | 19.8 ± 4.1 |
| Change from Baseline at Week 12_4 PM (n=61,63) | -1.3 ± 2.7 | -2.4 ± 3.5 |
IOP is a measurement of the fluid pressure in the eye. The mean diurnal IOP was the average of the IOP values of the study eye (worse eye) measured at 8 AM, 12 Noon and 4 PM. For each eye, IOP was either the average of 2 measurements, or, if a third measurement was required, the average of 3 measurements.
| percentage of participants | LUMIGAN® RC | DuoTrav® |
|---|---|---|
| Percentage of Participants With ≥15% Reduction in Mean Diurnal IOP From Baseline | 26.2 | 47.6 |
IOP is a measure of the fluid pressure in the eye. The mean diurnal IOP was the average of the IOP values of the study eye (worse eye) at Week 12 measured at 8 AM, 12 Noon and 4 PM. For each eye, IOP was either the average of 2 measurements, or, if a third measurement was required, the average of 3 measurements.
| percentage of participants | LUMIGAN® RC | DuoTrav® |
|---|---|---|
| Percentage of Participants With Mean Diurnal IOP Less Than 18 mmHg | 11.5 | 17.5 |
IOP is a measurement of the fluid pressure inside the eye. IOP of the study eye (worse eye) was measured at 8 AM, 12 Noon and 4 PM at Week 6. For each eye, IOP was either the average of 2 measurements, or, if a third measurement was required, the average of 3 measurements. A negative change from Baseline indicated improvement.
| mmHg | LUMIGAN® RC | DuoTrav® |
|---|---|---|
| Baseline_ 8 AM | 22.0 ± 2.9 | 22.0 ± 4.1 |
| Change from Baseline at Week 6 _8 AM (n=66,64) | -2.8 ± 2.9 | -4.8 ± 4.1 |
| Baseline_12 Noon | 20.6 ± 3.2 | 20.3 ± 3.8 |
| Change from Baseline at Week 6_12 Noon (n=66,64) | -2.1 ± 3.1 | -2.8 ± 3.4 |
| Baseline_4 PM | 19.8 ± 3.1 | 19.8 ± 4.1 |
| Change from Baseline at Week 6_4 PM (n=66,64) | -1.5 ± 2.5 | -2.9 ± 3.6 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Travatan® Z | — | 0/135 (0%) | 0/135 (0%) |
| LUMIGAN® RC | — | 0/67 (0%) | 0/67 (0%) |
| DuoTrav® | — | 1/68 (1.5%) | 0/68 (0%) |
| Event | Travatan® Z | LUMIGAN® RC | DuoTrav® |
|---|---|---|---|
| PyrexiaGeneral disorders | 0/135 | 0/67 | 1/68 |
| CellulitisInfections and infestations | 0/135 | 0/67 | 1/68 |
| Age, Continuous(Years) | LUMIGAN® RC | DuoTrav® | Total |
|---|---|---|---|
| Mean | 67.2 ± 9.7 | 65.2 ± 10.7 | 66.2 ± 10.3 |
| Sex: Female, Male(Participants) | LUMIGAN® RC | DuoTrav® | Total |
|---|---|---|---|
| Female | 40 | 40 | 80 |
| Male | 27 | 28 | 55 |
The record gives a start of Dec 2011, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Travoprost · Bimatoprost Ophthalmic Solution